Thermo Fisher stock price rises nearly 2% as Australia starts Clario deal review; earnings next in focus
New York, January 21, 2026, 11:46 EST — Regular session Thermo Fisher Scientific Inc (NYSE: TMO) shares climbed roughly 1.9% to $630.48 Wednesday, outpacing the broader market as investors digested new regulatory developments around its planned Clario acquisition. The stock hit an intraday high of $631.25 earlier in the session. The Australian Competition and Consumer Commission (ACCC) has launched a Phase 1 review — its preliminary check — of Thermo Fisher’s planned acquisition of Clario, the regulator’s acquisitions register shows. The ACCC marked the deal as “under assessment” and gave itself a deadline of March 2 for a decision. (ACCC)